Hikma launches Clobazam oral suspension and Clobazam tablets

Published: 11-Dec-2018
Pharmaceutical

Hikma Pharmaceuticals has launched Clobazam oral suspension, 2.5 mg/mL, and Clobazam tablets, 10 and 20 mg, the generic equivalent to Onfi


Hikma’s Clobazam is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

According to IQVIA, US sales of Clobazam oral suspension were approximately $260 million and of Clobazam tablets were approximately $601 million in the 12 months ending September 2018.

Brian Hoffmann, President, Generics Division, said: “We are very excited to add Clobazam oral suspension and Clobazam tablets to our product portfolio. This will be among the first generics available on the market and we are pleased to improve patients’ access to this important medicine.”

  • Companies:
  • Hikma Pharmaceuticals
See more

You may also like

Manufacturing

Hikma establishes distribution partnership with Melinta

Read more
The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Why use corrugated tubes in heat exchangers? There are a variety of tubular heat exchangers on the market, but for many applications corrugated tubes continue to be preferred over smooth ones. Matt Hale, International Sales & Marketing Director of HRS Heat Exchangers, explains why
  5. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Hikma establishes distribution partnership with Melinta

The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region
Distribution

Hikma announces exclusive agreement with Sciecure Pharma for niche injectable antiviral medicine

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world
Regulatory

Hikma launches Dalfampridine Extended-release tablets

Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Drug Delivery

Hikma announces agreement with Vectura to develop generic salmeterol for the US market

Hikma is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products
Finance

Hikma to buy Boehringer Ingelheim's Roxane business for US$2.65bn in cash and stock

Will boost its presence in US generics market
Finance

Hikma completes purchase of assets of Bedford Laboratories

Strengthens position as a leading generic injectables company in the US
Drug Delivery

Hikma signs transdermal patch supply agreement with SK Chemicals of South Korea

For the first approved generic Rivastigmine transdermal patch for dementia in Alzheimer\'s disease
Subscribe now